EOLS News and Press, Evolus Inc. From 05/10/22

Evolus, Inc. (EOLS) Q1 2022 Earnings Conference Call May 10, 2022, 04:30 PM ET Company Participants David Erickson - Vice President-Investor Relations David Moatazedi - President and Chief Executive Officer Lauren Silvernail - Chief Financial Officer and Executive Vice President, Corporate De...

Evolus press release (NASDAQ:EOLS): Q1 GAAP EPS of -$0.31 beats by $0.12. Revenue of $33.91M (+177.0% Y/Y) beats by $4.08M. Now expects sales to reach the upper end of its full-year sales guidance range of $143M to $150M. Cash position of $106.7M expected to fund company to breakeven. For f...

Q1 2022 Net Revenue of $33.9 Million, Up 177% from Q1 2021 Now Guiding to Upper End of Full-Year 2022 Net Revenue of $143 to $150 Million Reiterating Full-Year non-GAAP Operating Expense Guidance Strong Cash Position of $106.7 Million Expected to Fund Company...

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that it will report its first quarter 2022 financial results and provide a business update on Tuesday, May 10, 2022, after the U.S. fin...

Medical aesthetics company Evolus (NASDAQ:EOLS) enrolled its first patient in a phase 2 study evaluating an "extra-strength" dose for extended duration of Jeuveau, its flagship neurotoxin drug to treat forehead wrinkles and frown lines. Jeuveau competes with Botox, made by AbbVie's ...

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, has enrolled its first patient in a clinical study evaluating an “extra-strength” dose for extended duration of Jeuveau ® (prabo...

Gainers: CarParts.com (PRTS) +6%. Opera Limited (OPRA) +5%. TMC the metals company  (TMC) +4%. Oric Pharmaceuticals (ORIC) +3%. MaxCyte (MXCT) +3%. Losers: Poshmark (POSH) -7%. XP  (XP) -5%. Vir Biotechnology (VIR) -5%. Evolus (EOLS) -4%. Grea...

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that members of its management team will be participating in the Barclays Global Healthcare Conference. An audio webcast of this ev...

Evolus, Inc. (EOLS) Q4 2021 Earnings Conference Call March 3, 2022 4:30 PM ET Company Participants David Erickson – Vice President-Investor Relations David Moatazedi – President and Chief Executive Officer Rui Avelar – Chief Medical Officer and Head-Research and Developme...

Evolus press release (NASDAQ:EOLS): Q4 GAAP EPS of -$0.33 beats by $0.07. Revenue of $34.7M (+68.6% Y/Y) misses by $0.07M. For further details see: Evolus GAAP EPS of -$0.33 beats by $0.07, revenue of $34.7M misses by $0.07M